Abstract P4-08-05: Delineation of HER2 Gene Status in Korean Breast Cancers by Standardized Immunohistochemistry (IHC) and Silver In Situ Hybridization (SISH): Comparison of Local IHC Result with Central IHC and SISH Results

2010 ◽  
Author(s):  
YK Bae ◽  
G Gong ◽  
J Kang ◽  
A Lee ◽  
EY Cho ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Breast Cancers ◽  
Her2 Gene ◽  
Silver In Situ Hybridization ◽  
Gene Status

P269 Silver in situ hybridization and FISH for determination of HER2 gene status in breast carcinoma

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S119
Author(s):  
A. Kram ◽  
M. Stepaniuk ◽  
L. Teresinski ◽  
E. Bocher ◽  
W. Ploszynska ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Her2 Gene ◽  
Silver In Situ Hybridization ◽  
Gene Status

scholarly journals Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists

2008 ◽  
Vol 10 (6) ◽  
pp. 527-536 ◽  
Author(s):  
Antonino Carbone ◽  
Gerardo Botti ◽  
Annunziata Gloghini ◽  
Gianni Simone ◽  
Mauro Truini ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Her2 Gene ◽  
Silver In Situ Hybridization ◽  
Gene Status

Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma

2010 ◽  
Vol 34 (6) ◽  
pp. 767-776 ◽  
Author(s):  
Bettina G. Papouchado ◽  
Jonathan Myles ◽  
Ricardo V. Lloyd ◽  
Mark Stoler ◽  
Andre M. Oliveira ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Her2 Gene ◽  
Silver In Situ Hybridization ◽  
Gene Status

scholarly journals Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Bo Wang ◽  
Wei Ding ◽  
Ke Sun ◽  
Xiaoling Wang ◽  
Liming Xu ◽  
...  
Keyword(s):  
Growth Factor Receptor ◽  
Breast Cancers ◽  
Her2 Gene ◽  
Her2 Positive ◽  
Group 2 ◽  
Gene Status ◽  
American Society ◽  
New Guidelines ◽  
The Impact

Abstract The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) recently issued updated guidelines on human epidermal growth factor receptor 2 (HER2) testing by fluorescence in situ hybridization (FISH) in invasive breast cancers. In this study, we aimed to investigate the impact of the new recommendations on HER2 FISH interpretation in invasive breast cancers with immunohistochemically (IHC) equivocal results. 1810 breast cancer cases with IHC equivocal results were enrolled in this study between January 2012 and May 2019. Concomitant IHC was performed on the same tissue blocks detected by FISH testing. According to the 2018 guidelines, all the cases in ISH group 2 were categorized as HER2 negative; three of four cases in ISH group 3 were considered as HER2 positive, while the one scored IHC 1+ was reclassified as HER2 negative; Fifty-three previously ISH equivocal cases were redistributed into ten HER2-positive cases and forty-three HER2-negative cases. In conclusion, the utility of 2018 ASCO/CAP guidelines resulted in a slight decrease in HER2 positive rate, due to the reclassification of cases in ISH group 2 and group 4. The implementation of the new guidelines can reduce reflex FISH test and make the diagnosis of HER2 gene status more definitive.

Sign in / Sign up

Export Citation Format

Share Document